Efficacy, Immunogenicity, and Safety of Modified mRNA Influenza Vaccine

The modRNA vaccine had statistically superior efficacy over the control vaccine, with greater immune responses to A/H3N2 and A/H1N1 strains, but was associated with more reactogenicity events. (Funded by Pfizer; C4781004 ClinicalTrials.gov number, NCT05540522.)See also in NEJM Evidence: Human clinical trial of a nucleoside-modified mRNA influenza vaccine.